Orexigen Therapeutics Inc reports grant of inducement stock option
Biopharmaceutical company Orexigen Therapeutics Inc reported on Thursday the grant of an inducement stock option to a new employee to purchase 9,000 shares of common stock.
Orexigen Therapeutics reports that its obesity drug Contrave has sailed through two late-stage trials and surpassed US Food and Drug Administration effectiveness requirements.